oa SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?

References

1. Krum H, Schlaich M, Whitbourn R, Sobotka P, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham W, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373::1275–1281.
   [Google Scholar]
2. Symplicity HTN-2 Investigators , Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010; 376::1903–1909.
   [Google Scholar]
3. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with a focus on trial design: the CONVERGE report. Heart. 2013; 99::1579–1587.
   [Google Scholar]
4. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators . A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370::1393–1401.
   [Google Scholar]
5. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57::898–902.
   [Google Scholar]
6. Howard JP, Cole GD, Sievert H, Bhatt DL, Papademetriou V, Kandzari DE, Davies JE, Francis DP. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014; 172::29–35.
   [Google Scholar]
7. Patel HC, di Mario C. Renal denervation for hypertension: where are we now? Br J Cardiol. 2013; 20::142–147.
   [Google Scholar]
8. Patel H, Rosen S, Lindsay A, Hayward C, Lyon A, di Mario C. Targeting the autonomic nervous system: measuring autonomic function and novel devices for heart failure management. Int J Cardiol. 2013; 170::107–117.
   [Google Scholar]
9. Patel H, Dhillon P, Mahfoud F, Lindsay A, Hayward C, Ersnt S, Lyon A, Rosen S, di Mario C. The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol. 2013; 103::337–344.
   [Google Scholar]
10. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double blind, placebo-controlled trial. Hypertension. 2011; 57::1069–1075.
    [Google Scholar]
11. Krum H, Schlaich M, Sobotka P, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler M. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014; 383::622–629.
    [Google Scholar]